Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2010

Quantification of indirect pathway inhibition by the adenosine A
2a antagonist SYN115 in Parkinson disease
Kevin J. Black
Washington University School of Medicine in St. Louis

Jonathan M. Koller
Washington University School of Medicine in St. Louis

Meghan C. Campbell
Washington University School of Medicine in St. Louis

Debra A. Gusnard
Washington University School of Medicine in St. Louis

Stephen I. Bandak
Synosia Therapeutics

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
Part of the Medicine and Health Sciences Commons

Recommended Citation
Black, Kevin J.; Koller, Jonathan M.; Campbell, Meghan C.; Gusnard, Debra A.; and Bandak, Stephen I.,
,"Quantification of indirect pathway inhibition by the adenosine A 2a antagonist SYN115 in Parkinson
disease." The Journal of Neuroscience. 30,48. 16284-16292. (2010).
https://digitalcommons.wustl.edu/open_access_pubs/230

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

16284 • The Journal of Neuroscience, December 1, 2010 • 30(48):16284 –16292

Neurobiology of Disease

Quantification of Indirect Pathway Inhibition by the
Adenosine A2a Antagonist SYN115 in Parkinson Disease
Kevin J. Black,1,2,3,4 Jonathan M. Koller,1 Meghan C. Campbell,2 Debra A. Gusnard,1,3 and Stephen I. Bandak5
Departments of 1Psychiatry, 2Neurology, 3Radiology, and 4Anatomy and Neurobiology, Washington University School of Medicine, St. Louis, Missouri
63110 and 5Synosia Therapeutics, South San Francisco, California 94080

Adenosine A2a receptor antagonists reduce symptom severity in Parkinson disease (PD) and animal models. Rodent studies support the
hypothesis that A2a antagonists produce this benefit by reducing the inhibitory output of the basal ganglia indirect pathway. One way to
test this hypothesis in humans is to quantify regional pharmacodynamic responses with cerebral blood flow (CBF) imaging. That
approach has also been proposed as a tool to accelerate pharmaceutical dose finding, but has not yet been applied in humans to drugs
in development. We successfully addressed both these aims with a perfusion magnetic resonance imaging (MRI) study of the novel
adenosine A2a antagonist SYN115. During a randomized, double-blind, placebo-controlled, crossover study in 21 PD patients on
levodopa but no agonists, we acquired pulsed arterial spin labeling MRI at the end of each treatment period. SYN115 produced a
highly significant decrease in thalamic CBF, consistent with reduced pallidothalamic inhibition via the indirect pathway. Similar
decreases occurred in cortical regions whose activity decreases with increased alertness and externally focused attention, consistent with decreased self-reported sleepiness on SYN115. Remarkably, we also derived quantitative pharmacodynamic parameters
from the CBF responses to SYN115. These results suggested that the doses tested were on the low end of the effective dose range,
consistent with clinical data reported separately. We conclude that (1) SYN115 enters the brain and exerts dose-dependent regional
effects, (2) the most prominent of these effects is consistent with deactivation of the indirect pathway as predicted by preclinical
studies; and (3) perfusion MRI can provide rapid, quantitative, clinically relevant dose-finding information for pharmaceutical
development.

Introduction
Measuring the sensitivity of a biological system to a drug is of
significant interest not only as a topic of basic research, but also as
a practical tool for pharmaceutical development, since dosefinding studies in humans are crucially important yet expensive
and often take months or years. New approaches to measuring
pharmacodynamic response are eagerly sought. One approach
has been to image the organ of interest while applying pharmacological stimuli (rather than cognitive tasks or sensory stimuli).
Pharmacological challenge imaging is especially relevant for
studies of the brain (Herscovitch, 2001; Wise and Tracey, 2006;
Lawrence and Mackey, 2008).
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Pharmacological challenge imaging was applied very early in
preclinical studies of the action of antiparkinsonian drugs (McCulloch and Harper, 1977; McCulloch et al., 1980b), and further
studies clarified the neuronal pathways that led to the effects on
cerebral blood flow (CBF) or metabolism and their alteration
with parkinsonism or anesthestics (McCulloch, 1982; McCulloch
et al., 1980a; Crosby et al., 1982; Trugman, 1995). This approach
was extended to in vivo neuroimaging in humans (Grasby et al.,
1993; Hershey et al., 1998; Black et al., 2005) and other primates
(Perlmutter et al., 1993; Black et al., 1997; 2000; 2002a,b; Hershey
et al., 2000). Even so, few pharmacological challenge studies produced dose–response information (Grasby et al., 1993; Perlmutter et al., 1993; Black et al., 1997, 2000, 2002a,b; Hershey et al.,
2000; Ireland et al., 2005; Kofke et al., 2007; Bruns et al., 2009),
and none provided quantitative characterization of a dose–response curve.
For technical reasons, blood oxygenation level-dependent
(BOLD)-sensitive functional magnetic resonance imaging (fMRI) is
difficult to apply to pharmacological challenge imaging (Iannetti
and Wise, 2007), though several labs have performed pharmacological challenge fMRI in nonhuman species or for drugs with a
short half-life (Chen et al., 1996, 1997, 2001; Ireland et al., 2005;
Borsook et al., 2007; Bruns et al., 2009). Blood-flow MRI does not
share the technical limitations of BOLD-sensitive methods, and
it builds on the successes of blood-flow positron emission
tomography (PET) in producing useful pharmacodynamic results (Herscovitch, 2001; Leslie and James, 2001). Recent stud-

Black et al. • Regional A2a Antagonist Effects Quantified by MRI

J. Neurosci., December 1, 2010 • 30(48):16284 –16292 • 16285

Written documentation of informed consent was
obtained in advance from each subject. Levodopa
and SYN115 were given under U.S. Food and
Drug Administration (FDA) Investigational New
Drug Application 78,230.
The study was conducted at the Center for
Clinical Imaging Research and the NeuroClinical Research Unit of Washington University
School of Medicine (St. Louis, MO) and registered at http://clinicaltrials.gov (identifier,
NCT00605553).
Study participants. Twenty-one nondemented, nondepressed adults age 40 –75 with
mild idiopathic PD [Hoehn and Yahr (1967)
stages 1–3], treated with a stable dose of levodopa but no dopamine agonists, participated
in the study. Detailed inclusion and exclusion
criteria were reported previously (Black et al.,
2010c).
Study protocol. In this crossover study, subjects were randomly assigned to one of two
treatment sequences: those assigned to sequence 1 took SYN115 twice daily for a week,
waited 1 week (washout period), and then took
a matching placebo twice daily for a week;
those assigned to sequence 2 participated in the
reverse order (Fig. 1a). Subjects and staff were
blind to SYN115-placebo sequence assignment. In 14 subjects, each SYN115 dose during
the active treatment week was 60 mg, and in 12
subsequent subjects the dose was 20 mg. Five
subjects who participated in the 60 mg placebo
segment later participated in the 20 mg placebo
Figure 1. Study design (see Materials and Methods, Study Protocol for important details). a, Top, Schematic showing the
segment, for a total of 21 distinct subjects.
temporal relationship of each subject’s scan days to his or her taking active study drug and placebo. b, Bottom, Schematic showing
Subjects were evaluated on the last day of
each subject’s participation on each of his or her two scan days. LD, Levodopa.
each treatment week (“scan days”) (Fig. 1b).
Subjects had abstained from food and all forms
of caffeine since the preceding evening. On the
ies have demonstrated the validity of applying perfusion MRI in
morning of the scan day, they did not take their usual antiparkinsonian
humans to study existing drugs (Borsook et al., 2007; Kofke et al.,
medications, but they took the last dose of SYN115 or placebo at approx2007; MacIntosh et al., 2008; Bruns et al., 2009). However, pracimately 6:00 A.M. After arrival at the imaging center, subjects took 200
mg of carbidopa by mouth and then underwent two sets of clinical and
tical and physiological issues have delayed useful applications;
MRI assessments, once before and once during an infusion of levodopa.
we have not located a published report of human pharmacoThe intravenous levodopa infusion was dosed so as to rapidly produce
logical challenge perfusion MRI successfully applied to an inand
then maintain a steady plasma concentration of 600 ng/ml (Gordon
vestigational new drug.
et al., 2007). The infusion was delivered through small-bore lightA2a receptor antagonists are being studied eagerly as potential
resistant Luer lock tubing (part 537235PS; Medex) from a model 44
alternative treatments for Parkinson disease (PD) (Fuxe et al., 2007).
syringe pump (Harvard Apparatus) inside an RF-shielded copper box
A2a receptors colocalize on striatopallidal neurons with dopamine
(Shielding Resources Group). The time-dependent infusion rate was
D2 and D3 receptors, which inhibit the so-called indirect basal gancontrolled by custom software written in Java (Sun Microsystems) runglia pathway from striatum to thalamus via globus pallidus pars
ning on a small solid-state laptop computer (Eee PC 2G; Asus) connected
externa, subthalamic nucleus (STN), and internal pallidum
to the pump’s serial port. The pump was powered through an uninter(Strömberg et al., 2000; Torvinen et al., 2005). A2a antagonists
ruptible power supply (battery backup) inside the copper box so that the
pump box could be moved with the patient without interrupting the
produce some of the same biological effects as dopamine D2 and
infusion.
D3 agonists (Tanganelli et al., 2004), yet it is not known whether
All MRI and clinical assessments were repeated while the maintenance
they also inhibit the indirect pathway, nor which “downstream”
levodopa infusion continued, beginning at least 25 min after the levocortical and subcortical regions of human brain are most sensidopa infusion started, i.e., after ⬃4⫻ the distribution half-life (t1/2␣) of
tive to A2a antagonism.
intravenous levodopa (Abraham et al., 2006). Blood samples for measurWe used perfusion MRI to answer these scientific questions
ing plasma levodopa concentrations were taken from an upper extremity
and to inform development of a new A2a receptor antagonist,
vein contralateral to the infusion site after the second assessment battery
SYN115. This work was presented in part at the annual meetings
of each day.
of the Society for Neuroscience, the American Academy of NeuThe timing of the clinical and fMRI assessments before and on levorology, and the Movement Disorders Society (Dickerson et al.,
dopa was planned to approximately bracket the Tmax of SYN115 (time to
2009; Black et al., 2010a,b).
maximal plasma concentration) after chronic dosing.
Behavioral state during fMRI scans. Each assessment battery mentioned
Materials and Methods
above included eight perfusion MRI scans. Each perfusion scan was acquired during a single behavioral task condition: two scans while the
Regulatory approvals, registrations, and patient consent. This study was approved by the Washington University Human Research Protection Office.
subject fixated a central crosshair surrounded by a circular checkerboard
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pattern reversing at 8 Hz, two scans while the subject performed a twoback letter working memory task, and four control visual fixation scans
with the crosshair but no checkerboard. The reversing checkerboard
scans were done as a positive control for the arterial spin labeling (ASL)
method so that if the study drug showed no activation we could test
whether ASL, as implemented in this study, was adequately sensitive to
changes in regional CBF (rCBF).
Quantification of plasma concentration of SYN115. SYN115 plasma concentrations were determined using a validated high-performance liquid
chromatography/tandem mass spectrometry (HPLC-MS/MS) assay (Frontage Laboratories). The method used protein precipitation of SYN115 from
human plasma followed by HPLC separation and MS/MS detection, with a
deuterated internal standard. Electrospray ionization and positive sample
mode were used on an API 4000 and 5000 platform. All sample analysis runs
used freshly prepared quality control samples. The assay was validated in the
concentration range of 10 –10,000 ng/ml.
MRI methods. All MRI data were acquired on the Siemens 3.0T Tim Trio
with a matrix head coil. ASL images were acquired with the commercial
Siemens pulsed ASL sequence (Wang et al., 2003) with 15 echoplanar readout slices parallel to the bicommissural line, at a center-to-center distance of
6.0 mm, 64 ⫻ 64 voxels in plane with dimensions (3.4375 mm) 2, a repetition
time (TR) of 2.6 s, an echo time (TE) of 13.0 ms, and a flip angle of 90°. An
M0 image was followed by 31 tag-control pairs for a total acquisition time
for each ASL “scan” of 2.73 min. Brain structure was assessed by averaging two mutually registered sagittal magnetization-prepared rapidacquisition gradient echo acquisitions with a voxel size of (1.0 mm) 3, TR
of 2.4 s, TE of 3.08 ms, inversion time of 1000 ms, and flip angle of 8°.
Creation of scaled CBF images. The 63 frames of the ASL run were
rigidly aligned using a validated method (Black et al., 2001) and summed
to facilitate later alignment steps. Each frame was smoothed using a
Gaussian filter with kernel measuring 7.35 mm [full-width at halfmaximum (FWHM)], and CBF was computed in each voxel for each
tag-control pair (Wang et al., 2003). The summed within-run-aligned
echoplanar images were mutually aligned within each subject and
summed, and the resulting image was affine registered to a target image
in Talairach and Tournoux space made using validated methods from
the structural MR images from these subjects (Black et al., 2004). From
this registration, the 31 tag-control-pair CBF images were resampled into
atlas space using matrix multiplication to avoid multiple resampling
steps and averaged to create a single atlas-registered CBF image for each
ASL run. One such image is shown in supplemental Figure 6 (available at
www.jneurosci.org as supplemental material).
Only those voxels were analyzed that were represented in every echoplanar image in every subject. The combined volume of these voxels was
1,231 ml (supplemental Fig. 7, available at www.jneurosci.org as supplemental material). Global or whole-brain mean CBF (gCBF) was computed across these voxels so that gCBF was computed from the same
brain region in every scan in every subject. However, for a given scan,
voxels whose value was ⬍20 or ⬎120 ml 䡠 hg ⫺1 䡠 min ⫺1 (i.e., physiologically unreasonable values) were excluded from this mean.
Regional analyses must account for possible changes in gCBF with
drug to avoid incorrectly interpreting results (Black et al., 2002b). Thus,
all analyses examining regional CBF removed the gCBF effect by scaling
all input images multiplicatively so that the global mean CBF for every
image was 50 ml 䡠 hg ⫺1 䡠 min ⫺1. This conventional approach to bloodflow imaging was prespecified for this study from the outset. Thus, any
decreases in regional CBF represent changes beyond that which could be
explained by the overall change in whole-brain average, or global, CBF.
Statistical methods. Our lab’s standard approach to pharmacological
activation analysis is to perform a voxelwise statistical parametric mapping (SPM) analysis to identify regional changes, using globally scaled
CBF images only from placebo and the highest dose of drug (Black et al.,
2004). This approach reduces the multiplicity of possible comparisons by
assuming that the drug effects of most interest are those that are largest in
magnitude (or most consistently present) at the highest dose of drug.
Regions identified as having significantly altered rCBF with drug are then
examined in images from lower doses.
In this study, we used a two-level, mixed-effects approach to analysis
with the goal of identifying only effects likely to be representative of the

entire population from which our subjects were sampled (Gläscher and
Gitelman, 2008). First, for each subject in the study, changes in rCBF
were identified from the 60 mg study arm using SPM8 software (www.
fil.ion.ucl.ac.uk/spm/) and a voxelwise general linear model that included factors representing study drug (SYN115 vs placebo), levodopa
(before vs during infusion), the drug by levodopa interaction, and task
(i.e., behavioral state during the scan: two-back working memory, 8 Hz
reversing circular checkerboard, or visual fixation). A statistical parametric image for each subject was generated from the drug contrast and a
second one from the drug by levodopa contrast.
Statistical inference for the entire study was done across subjects in a
second-level SPM analysis. The contrast images generated for each subject as described in the preceding paragraph were the input data for a
voxelwise general linear model that included a covariate for subject age
(in years) and factors for subject sex (male, female) and dose of SYN115
in the active capsules (20 or 60 mg). Statistical inference was performed at
each voxel with a one-sample t test (i.e., testing across subjects whether the
drug contrast subject images are significantly less than or greater than zero).
Multiple-comparisons correction was performed at the cluster level
with the false discovery rate set at p ⫽ 0.05, according to our prespecified
analysis strategy. However, to minimize type II error, we also list in
supplemental Table 3 (available at www.jneurosci.org as supplemental
material) all peaks with uncorrected p values ⬍0.001. Highlighted entries
in this table indicate peaks that would be considered significant by a
different statistical criterion, such as single-voxel (magnitude-based)
false discovery rate correction. In this data set, the Bonferroni correction
would accept as significant all voxels with t ⬎ 4.8.
Approximate anatomical locations were provided by the Talairach
Daemon client (www.talairach.org) (Lancaster et al., 2000), with corrections by reference to the study-specific MRI template atlas image.
Image sampling and VOI definition. Local maxima (“peaks”) from significant clusters were selected for additional analysis. Mean rCBF values
representing each peak were derived from a 12-mm-diameter spherical
VOI centered at the peak. This diameter corresponds to the 10 –12 mm
resolution (FWHM) of the data as estimated by SPM. These VOIs were
masked to include only voxels with t values exceeding the value corresponding to p ⬍ 0.001 (uncorrected) and only voxels represented in the
final mask (supplemental Fig. 7, available at www.jneurosci.org as supplemental material).
Pharmacodynamic parameter estimation. We estimated the classic
pharmacodynamic parameters Emax (maximal effect) and EC50 (drug
concentration in plasma that produces an effect equal to 50% 䡠 Emax)
using custom software by Bretthorst (1988) that implements a Markov
chain Monte Carlo simulation method. The equation is E( C) ⫽ E(0) ⫹
Emax 䡠 Cn / (EC50n ⫹ Cn), where n is the Hill coefficient (unitless) that
controls the steepness of the sigmoid curve. The independent variable C
is the plasma concentration in nanograms per milliliter of SYN115 sampled in the prelevodopa or on-levodopa state in which the corresponding
ASL images were obtained. The dependent variable E, effect of drug, was
each subject’s fractional change in mean rCBF in the VOI centered at the
SPM peak, relative to the prelevodopa value from that subject’s placebo
day (Eli Lilly and Company and NIH Chemical Genomics Center, 2008).
Data from the 20 and 60 mg arms were considered together. Prior probabilities are given in supplemental Table 4 (available at www.jneurosci.org as
supplemental material). The appropriateness of the pharmacodynamic
model to these data was quantified by the probability that it better explained
the data than a polynomial with the same number of free parameters.

Results
Every subject who took any dose of study drug or placebo completed every scheduled MRI scan at every assessment session,
except for one subject who was discharged from the 20 mg arm of
the study on the morning of the first assessment day because of
noncompliance. This subject had already participated without
error in the 60 mg arm but is not counted in the 12 subjects who
completed the 20 mg arm. Thus, for all included subjects, all
scheduled CBF scans were included in the analyses, for a total of
832 CBF scans (derived from 52,416 echoplanar image volumes).
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Table 1. Significant decreases in rCBF on the higher dose of SYN115 compared with placebo
Cluster

Volume of cluster (in ml)

Peak t value (11 df)

Location of peak t value

Anatomic description of cluster

1

51.4

19.51

Right dorsomedial thalamus

2
3
4
5
6
15
22

12.1
9.7
8.7
2.8
2.8
1.4
0.9

14.27
9.59
7.74
6.81
6.71
5.45
4.90

Right anterior cingulate cortex (BA 32)
Left prefrontal cortex (lateral to BA 32)
Left middle frontal gyrus (BA 6)
Right postcentral gyrus (BA 2)
Left superior parietal lobule (BA 7)
Right precentral gyrus (BA 6)
Right medial frontal gyrus (BA 9)

Bilateral thalamus, precuneus (BA 7, 23, 31), midbrain, cuneus
(BA 7, 18), posterior cingulate (BA 23, 29, 30)
Bilateral anterior cingulate (BA 32), medial frontal gyrus (BA 9, 11)
Left middle and inferior gyri (BA 8, 9, 45, 46), precentral gyrus (BA 44)
Left middle and precentral gyri (BA 6, 4)
Right postcentral gyrus (BA 2)
Left superior parietal lobule (BA 7)
Right precentral and medial frontal gyri (BA 6)
Right medial frontal gyrus (BA 9)

See supplemental Table 3 (available at www.jneurosci.org as supplemental material) for additional details.

mg, p.o., b.i.d., 7%, p ⬍ 0.001). As noted
in Materials and Methods, this change in
gCBF with the drug was removed from the
images before proceeding to the analyses
described below.
Decreases in rCBF with SYN115
SYN115 induced highly significant decreases in regional CBF. Eight clusters met
the predefined criteria for statistical significance after correction for multiple
comparisons (Table 1). The first cluster
(corrected p ⬍ 10 ⫺31) had its peak t value
in thalamus but also extended into midbrain, precuneus, cuneus, and cerebellum
(Fig. 2a,d). Volumes of interest (VOIs)
from seven t value local maxima (“peaks”)
from this cluster were selected for additional analysis (left and right thalamus,
left and right midbrain, precuneus [Brodmann’s area (BA) 7, BA 31], and posterior
cingulate [BA 30]), as described in Materials and Methods; atlas coordinates for
the center of each VOI are given in supplementalTable3(availableatwww.jneurosci.
org as supplemental material). Figure 2c
highlights the peak voxel from cluster 2.
For completeness, supplemental Table 3
(available at www.jneurosci.org as suppleFigure 2. a, Statistical image (color) representing the 兩t兩 values from the contrast (rCBF on SYN115 60 mg, b.i.d.) ⬍ (rCBF on
mental material) lists every local maximum
placebo), laid over the study-specific MRI template image (grayscale). The right side of the brain is displayed on the right side of the
in the thresholded 兩t兩 image that was sepacoronal image and the bottom of the axial image. The color t image shows all voxels for which 兩t兩 ⱖ 4.03 (corresponding to p ⬍
0.001, uncorrected). The orthogonal hairlines in each cross section identify the location of the other two cross sections and cross at rated from other maxima by ⱖ8 mm). To
the voxel in right thalamus with the highest 兩t兩 in the whole image (19.51; 11 df). b, Dose-dependent decrease in rCBF with SYN115 check the specificity of our results, we rein the right and left thalamus VOIs defined as described in Materials and Methods. c, d, The same image and conventions described peated the analysis using only those CBF
in a, with different cross sections chosen to display other peak 兩t兩 values. c, Hairlines cross at the peak 兩t兩 value from cluster 2. d, scans acquired off levodopa during the viHairlines cross at the local peak that defined VOI 3 from cluster 1 (in precuneus). For coordinates and anatomical descriptions, see sual fixation condition; results were similar
Table 1 and supplemental Table 3 (available at www.jneurosci.org as supplemental material).
(supplemental Fig. 8, available at www.
jneurosci.org as supplemental material).
Subjects were, on average, 60.8 years old (range, 44 –73), had a
As mentioned, the most statistically significant decreases in
5.3 year mean duration of PD symptoms (range, 0.9 –10.8), and
blood flow with 60 mg b.i.d. SYN115 occurred in bilateral thala12 of the 21 had ever experienced dopa-induced dyskinesias. All
mus (Fig. 2a). The rCBF changes at these regions were dose responwere Caucasian and right-handed, and 8 of the 21 were women.
sive (Fig. 2b). The decreases in the right thalamus VOI were even
Compliance was excellent as assessed by pill counts. The levolarger in the original images, before removing the whole-brain
dopa infusion produced plasma concentrations of 816 ⫾ 168
(mean global) CBF decrease (20 mg, ⫺10.4%; 60 mg, ⫺19.0%).
ng/ml (mean ⫾ SD), and plasma concentrations did not differ
significantly between conditions (t test, p ⬎ 0.20).
Dose responsiveness of rCBF decreases
The regions with decreased rCBF were identified using only the
Whole-brain blood-flow effects
images acquired in subjects who took the higher dose of SYN115.
SYN115 induced a small dose-dependent decrease in mean global
Nevertheless, across the 20 VOIs listed in Table 2, the rCBF deCBF (20 mg, p.o., b.i.d., mean 4%, p ⬍ 0.001 by paired t test; 60
creases were consistently greater in magnitude at the higher dose
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Table 2. Pharmacodynamic parameters calculated from SYN115 blood levels and corresponding rCBF changes
SYN115 only
VOI

Atlas coordinate

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

10.5
⫺7.5
13.5
1.5
19.5
10.5
⫺4.5
⫺7.5
1.5
10.5
4.5
⫺7.5
⫺4.5
7.5
⫺7.5
7.5
⫺4.5
⫺13.5
⫺13.5
⫺16.5

⫺21
⫺18
⫺66
⫺33
⫺69
⫺27
⫺51
45
30
45
12
21
6
⫺36
⫺60
⫺78
⫺33
⫺15
⫺9
15

12
12
36
⫺3
18
⫺15
18
9
33
⫺12
33
39
51
60
63
12
⫺9
63
⫺18
3

SYN115 ⫹ levodopa

Name

EC50

Emax

n

Prob. model

Prob. poly

EC50

Emax

n

E0

Prob. model

Prob. poly

Right thalamus
Left thalamus
Precuneus, BA 7
Midbrain
Precuneus, BA 31
Midbrain
Posterior cingulate, BA 30
Anterior cingulate, BA 32
Medial frontal gyrus, BA 9
Medial frontal gyrus, BA 11
Cingulate gyrus, BA 32
Middle frontal gyrus, BA 8
Middle frontal gyrus, BA 6
Postcentral gyrus, BA 2
Superior parietal lobule, BA 7
Cuneus, BA 17
Parahippocampal gyrus, BA 36
Precentral gyrus, BA 6
Temporal lobe, BA 20
Head of right caudate

966
942
460
202
220
1044
208
717
699
808
1449
825
1080
643
623
210
625
1014
502
541

⫺30
⫺29
⫺13
⫺15
⫺7
⫺32
⫺15
⫺12
⫺8
⫺6
⫺12
⫺20
⫺18
⫺14
⫺14
⫺7
⫺6
⫺17
⫺15
⫺13

0.95
1.07
8.47
1.05
2.34
1.78
0.80
7.88
7.45
1.62
3.51
1.45
2.44
1.13
2.07
1.50
6.06
2.92
2.77
3.36

0.94
0.92
0.96
0.92
0.88
1.00
0.88
0.98
0.92
0.98
0.98
0.92
0.96
0.90
0.96
0.92
0.98
0.96
0.98
0.94

0.06
0.08
0.04
0.08
0.13
0.00
0.13
0.02
0.08
0.02
0.02
0.08
0.04
0.10
0.04
0.08
0.02
0.04
0.02
0.06

917
779
1113
1344
495
1018
947
713
831
939
1525
1031
874
1281
829
465
664
716
1138
984

⫺16
⫺15
⫺17
⫺12
⫺11
⫺21
⫺7
⫺15
⫺3
⫺9
⫺9
⫺10
⫺19
⫺25
⫺11
⫺8
⫺9
⫺34
⫺21
⫺21

4.03
7.10
1.85
4.24
8.32
4.31
4.11
9.79
1.71
3.27
3.05
2.42
3.33
3.89
3.33
7.30
1.83
2.83
3.70
5.15

⫺1.8
⫺1.2
⫺2.6
⫺2.5
1.2
1.9
⫺7.1
1.0
⫺6.4
0.6
2.0
⫺4.9
⫺1.2
2.2
2.3
⫺1.2
2.7
9.1
1.0
⫺0.1

0.96
1.00
0.96
0.94
0.96
0.98
0.98
1.00
0.96
0.98
0.98
0.98
0.98
1.00
0.98
0.96
0.98
1.00
1.00
1.00

0.04
0.00
0.04
0.06
0.04
0.02
0.02
0.00
0.04
0.02
0.02
0.02
0.02
0.00
0.02
0.04
0.02
0.00
0.00
0.00

For details, see Materials and Methods, Pharmacodynamic parameter estimation. LD, Levodopa; Prob. model, probability of full model; Prob. poly, probability of polynomial. For VOIs, numbers are from the penultimate column in supplemental Table 3
(available at www.jneurosci.org as supplemental material); for example, VOI 8 is centered at the peak 兩t兩 value in cluster 2.

than at the lower dose (before levodopa, 18 of 20 VOIs; after
levodopa, 20 of 20 VOIs). We performed secondary SPM analyses
to test whether this dose-responsive pattern was an artifact of
selecting the VOIs from the higher-dose group only and concluded that it was not (results from an analysis of the five subjects
who had data from both doses of active drug are given in supplemental Table 5, available at www.jneurosci.org as supplemental
material, and results from a similar analysis across both dose
groups are in supplemental Table 6, available at www.jneurosci.
org as supplemental material).
Quantifying SYN115 potency
The placebo/20 mg/60 mg dose–response plot does not allow
estimation of EC50. We exploited the inherent pharmacokinetic
variability across subjects to create a group concentrationresponse curve (Fig. 3) for the rCBF change in each of the VOIs
identified in supplemental Table 3 (available at www.jneurosci.
org as supplemental material) and Table 2. We summarize here
the results from thalamus and midbrain VOIs. In each case, the
pharmacodynamic model was the more appropriate model
(probability, 92–100%) (Table 2). In the before-levodopa state,
the estimated maximum possible SYN115 effect on rCBF (Emax)
was a 29 –30% decrease in thalamus and a 15–32% decrease in
midbrain. Left midbrain (near superior colliculus; EC50 ⫽ 202
ng/ml) was more sensitive than thalamus (EC50 ⫽ 942–966 ng/
ml) and right midbrain (near substantia nigra pars reticulata and
pons, 1044 ng/ml). The Hill coefficient n was ⬃1 for these VOIs,
indicating a gradual increase in signal magnitude as blood concentration rises (Fig. 3, open double-line curve). The model ascribed a small effect on blood flow in these regions to levodopa
itself (indicated by the nonzero E0 entries in Table 2). In scans
acquired during the levodopa infusion, the rCBF response to
SYN115 changed more sharply over a narrower range of SYN115
concentrations (n ⫽ 4.03–7.10) (Fig. 3, solid curve), and thus the
concentrations actually observed in our study came closer to producing the maximal predicted rCBF response (Emax).
Increases in rCBF with SYN115 and levodopa effects
No statistically significant clusters were found for relative increases in rCBF with SYN115 or for the drug by levodopa inter-

Figure 3. The pharmacokinetic variability across subjects was exploited to create a population dose–response curve for the rCBF change in the right dorsomedial thalamus VOI. For additional details, see Results, Quantifying SYN115 potency for decreasing rCBF as a function of
plasma concentration.

action. The study was not designed to examine changes in rCBF
with levodopa, and an SPM analysis found no significant decreases, but rCBF increased significantly with levodopa in one
small cluster with peak values in the right putamen, claustrum,
and insula (supplemental Table 8, available at www.jneurosci.org
as supplemental material).

Discussion
The A2a antagonist SYN115 substantially decreased CBF in mediodorsal thalamus, midbrain, precuneus, and cingulate cortex.
Since direct vascular effects would apply to all regions of the
brain, the most likely explanation for the regionally specific CBF
effects is that SYN115 crosses the blood– brain barrier and alters
neuronal firing. The dose-responsive nature of the rCBF effects
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Figure 4. Expected effects in the indirect pathway of giving an A2a antagonist. See also
Discussion, Physiological interpretation of results, and supplemental Table 7 (available at www.
jneurosci.org as supplemental material). GPe, Globus pallidus, pars externa; GPi, globus pallidus, pars interna.

strongly suggests that they reflect pharmacological effects of
SYN115 in the brain.
Perfusion MRI in pharmaceutical development
The results answer the primary questions posed in the introduction: SYN115 causes pharmacodynamic effects in the brain, and
they are greater at the higher dose. The quantitative EC50 estimates (Fig. 3, Table 2) suggest that an even higher dose may be
more effective in terms of thalamic CBF response and perhaps
also clinically. Confirmation of that hypothesis will require a
large clinical study, but in this study a measure of motor speed
improved significantly only on the higher dose of SYN115 (Black
et al., 2010c).
Kofke et al. (2007) reported CBF effects of remifentanil, an
FDA-approved opioid agonist, at three doses in six human brain
regions chosen a priori, and similar results were reported in other
species (see Introduction). However, to our best knowledge, no
previous pharmacological challenge neuroimaging study has calculated quantitative EC50 values.
Physiological interpretation
An important question is which neurons are responsible for these
rCBF changes. Numerous studies provide evidence that the metabolic response to stimulation of a neuron occurs primarily at the
axon termini (Buzsáki et al., 2007), including a [18F]fluorodeoxyglucose PET study in PD patients whose globus pallidus internal
segment electrical activity was measured invasively (Eidelberg et
al., 1997). Thus, rCBF changes most likely reflect changes in the
firing of afferent neurons. With this principle in mind, Figure 4
shows how the known pharmacology and anatomy of the basal
ganglia predict this study’s most significant result (supplemental
Table 7, available at www.jneurosci.org as supplemental material). These results also accord with an 8 –12% increase in thalamic glucose metabolism in untreated PD and the reduction of
this increase by antiparkinsonian treatments (Ma et al., 2009).
After thalamus, the brain regions most significantly affected
by SYN115 were the anterior cingulate (BA 32) and precuneus
(BA 7, BA 23, and BA 31) (Fig. 2c,d; supplemental Table 3, available at www.jneurosci.org as supplemental material). The precuneus has several distinctive properties: in the fully awake alert
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Figure 5. Regional CBF responses to levodopa and to specific dopamine receptor agonists
from previous studies. Note the midbrain response in all studies and the thalamus and posterior
cingulate responses in the D2 and D3 agonist studies. a, Levodopa/carbidopa in PD and healthy
controls (Hershey et al., 1998). b, Levodopa/carbidopa in advanced PD (Black et al., 2005). c,
Levodopa/carbidopa in baboon (Hershey et al., 2000). d, Dopamine D1 agonist SKF82958 in
baboon (Black et al., 2000). e, Dopamine D2 agonist U91356a in baboon (Black et al., 2002a). f,
Dopamine D3 ⬎ D2 agonist pramipexole in baboon (Black et al., 2002b). c and d are from
additional, unpublished analyses of the data collected for the publications named above.

state, it consumes ⬃35% more glucose by weight than any other
human cortical region (Gusnard et al., 2001), and its metabolism
and rCBF decrease markedly in various states of reduced or absent consciousness (e.g., slow-wave sleep, propofol-induced anesthesia, and vegetative states) (Cavanna and Trimble, 2006).
This may be relevant since SYN115 at 60 mg p.o. b.i.d. decreased
self-reported sleepiness (Campbell et al., 2010). The precuneus
and anterior cingulate are also key components of the defaultmode network, a network of brain regions with high tonic activity
at rest that is significantly attenuated during goal-directed tasks
(Raichle et al., 2001). Dopamine D2 and D3 agonists reduced
rCBF in these regions (Fig. 5), and a recent report suggested a
dopaminergic link between attention and precuneus deactivation
(Tomasi et al., 2010). In fact, an fMRI study reported anomalous
precuneus and adjacent posterior cingulate responses in PD patients, compared to control subjects, during performance of an
executive function task (van Eimeren et al., 2009).
Comparison with caffeine effects
Most existing data on CBF effects of adenosine blockade come
from studies of the nonspecific adenosine receptor antagonist
caffeine. Caffeine has complex effects on cerebral metabolism and
blood flow, so it is important to consider how, or whether, they
inform interpretation of the results with a specific A2a antagonist.
Adenosine increases CBF (Joshi et al., 2002), whereas caffeine
decreases CBF by ⬃30% (Cameron et al., 1990; Perthen et al.,
2008). This CBF decrease is fairly uniform throughout the brain
(Mathew et al., 1983; Mathew and Wilson, 1985; Gotoh et al.,
2001; Cameron et al., 1990) and unrelated to changes in respiration (Cameron et al., 1990; Mathew et al., 1983). This effect has
been detected with ASL (Laurienti et al., 2003; Liu et al., 2004;
Bendlin et al., 2007; Perthen et al., 2008). Metabolic studies show
that direct vascular effects may produce this CBF decrease, since
caffeine actually increased glucose utilization (Grome and Ste-
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fanovich, 1986; Schroeder et al., 1989; Nehlig et al., 1994; Gotoh
et al., 2001). This uncoupling of CBF from metabolism led to a
period of interest in the use of caffeine as a BOLD signal booster,
though later work has been less enthusiastic. The uncoupling is
likely mediated by adenosine receptors, since another nonspecific
antagonist replicated the effect (theophylline) (Grome and Stefanovich, 1986). For these reasons, cerebral metabolism may be
more informative than CBF about the effects of caffeine on local
neuronal activity. Regional effects of caffeine on cerebral glucose
metabolism are strongest and most potent in dopamineinfluenced brain regions such as habenula, caudate, ventral tegmental area, amygdala, and medial and lateral thalamus (Nehlig
et al., 1994; Nehlig and Boyet, 2000, their Table 2; Gotoh et al.,
2001, their Fig. 3).
However, caffeine’s effects probably differ substantially from
those of specific A2a antagonists. The metabolic increases induced
by caffeine appear to be mediated by A1 receptors on neurons,
whereas its global effects on blood flow are likely mediated by
vascular A2a receptors (Blood et al., 2003; Kochanek et al., 2005).
This mechanism is presumably responsible for the modest global
decrease in CBF caused by SYN115.
Regional brain effects of specific A2a antagonists
Crucially, A2a receptors also occur on neurons, and selective A2a
antagonists exert clinical, electrophysiological, and metabolic effects. Therefore, one also expects regionally specific CBF effects
caused by the neuronal actions of the drug, and these must be
identified separately from the known direct vascular effects,
which are global in nature. We contend that we have accomplished this for the first time in humans in the present study, but
data from other species support our results. The A2a antagonist
DMPX (3,7-dimethyl-1-propargylxanthine) decreased glucose
utilization in the rodent globus pallidus (Nehlig et al., 1994),
consistent with the finding that A2a antagonists reduce striatopallidal firing (Strömberg et al., 2000). DMPX also decreased regional blood volume by 6 –10% in thalamus, striatum, and
olfactory tubercle (Chen et al., 2005).
The rCBF changes shown in Figure 2 are comparable to those
seen in 2DG and PET studies of dopamine agonists or levodopa
(Fig. 5). The regions of brain most sensitive to D2 and D3 receptor
agonists included midbrain, posterior cingulate cortex, prefrontal cortex, striatum, and thalamus (Trugman et al., 1991; Hershey
et al., 1998, 2000; Black et al., 2000, 2002b, 2005). This correspondence may be expected given that A2a antagonists are thought to
produce antiparkinsonian activity via facilitation of dopamine
D2/D3 receptor effects.
Limitations
Crossover trial designs are susceptible to carryover effects. However, carryover effects are very unlikely in this study: on the placebo day, subjects either received no previous SYN115 or
discontinued it ⬎20 half-lives earlier.
Although the most significant result, decreased thalamic
rCBF, is consistent with inhibition of the indirect pathway, that
model does not predict all our results. No significant rCBF increase was detected in the STN, though partial volume effects
may have hindered detection of CBF changes in this small nucleus (Borghammer et al., 2009). Furthermore, the classical basal
ganglia model does not predict the rCBF decrease observed in
cortex. However, neither does it predict the similar cortical rCBF
decrease observed with D2 and D3 dopamine agonists (Fig. 5e,f ).
This observation lends credence to the idea that cortical rCBF
responses are more complex than the indirect pathway model

alone can predict. After all, most cortical areas receive input from
cortical areas including homologous contralateral cortex and local recurrent axons and interneurons (supplemental Table 7,
available at www.jneurosci.org as supplemental material). One
may even speculate that the cortical rCBF changes found in this
study may prove to have predictive value in identifying medications with effects similar to those of dopamine D2 and D3
agonists.
Study participants self-selected for willingness to participate
in research and met strict exclusion criteria. Nevertheless, they
are clinically typical and had a range of levodopa dosing and
comorbid conditions, so these results probably reflect early stage
PD generally. The study also excluded patients taking dopamine
agonists, but this exclusion strengthens confidence in our interpretation that SYN115 itself is responsible for the pallidothalamic
inhibition seen here, rather than a possible interaction of SYN115
with a long-acting D2/D3 agonist.
Finally, we studied patients exposed to SYN115 for 1 week,
and single doses or chronic dosing may show additional or different effects. These limitations should be balanced against the
strengths of this work, including careful experimental design and
a conservative statistical analysis.
Implications
These results suggest hypotheses about how adenosine A2a antagonists may exert antiparkinsonian or alerting effects and identify
brain regions to which electrophysiological methods may be directed to test these hypotheses. Additionally, these results demonstrate the potential for pharmacological challenge perfusion
imaging to jump-start human dose selection in pharmaceutical
development. This study provided dose-finding information
quite rapidly compared with a typical clinical trial, and from
relatively few subjects.
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Strömberg I, Popoli P, Muller CE, Ferre S, Fuxe K (2000) Electrophysiological and behavioural evidence for an antagonistic modulatory role of

Black et al. • Regional A2a Antagonist Effects Quantified by MRI
adenosine A2A receptors in dopamine D2 receptor regulation in the rat
dopamine-denervated striatum. Eur J Neurosci 12:4033– 4037.
Tanganelli S, Sandager NK, Ferraro L, Antonelli T, Kehr J, Franco R, Ferre S,
Agnati LF, Fuxe K, Scheel-Kruger J (2004) Striatal plasticity at the network level. Focus on adenosine A2A and D2 interactions in models of
Parkinson’s Disease. Parkinsonism Relat Disord 10:273–280.
Tomasi D, Volkow ND, Wang R, Telang F, Wang G-J, Chang L, Ernst T,
Fowler JS (2010) Dopamine transporters in striatum correlate with deactivation in the default mode network during visuospatial attention.
PLoS ONE 4:e6102.
Torvinen M, Marcellino D, Canals M, Agnati LF, Lluis C, Franco R, Fuxe K
(2005) Adenosine A2A receptor and dopamine D3 receptor interactions:
evidence of functional A2A/D3 heteromeric complexes. Mol Pharmacol
67:400 – 407.
Trugman JM (1995) D1/D2 actions of dopaminergic drugs studied with
[14C]-2-deoxyglucose autoradiography. Prog Neuropsychopharmacol
Biol Psychiatry 19:795– 810.
Trugman JM, James CL, Wooten GF (1991) D1/D2 dopamine receptor
stimulation by L-DOPA. Brain 114:1429 –1440.
van Eimeren T, Monchi O, Ballanger B, Strafella AP (2009) Dysfunction of
the default mode network in Parkinson disease: a functional magnetic
resonance imaging study. Arch Neurol 66:877– 883.
Wang J, Licht DJ, Jahng GH, Liu CS, Rubin JT, Haselgrove J, Zimmerman RA,
Detre JA (2003) Pediatric perfusion imaging using pulsed arterial spin
labeling. J Magn Reson Imaging 18:404 – 413.
Wise RG, Tracey I (2006) The role of fMRI in drug discovery. J Magn Reson
Imaging 23:862– 876.

